Same Price & Trial Data: Scotland OKs Spravato Funding After England Says No
Discrepancy in access to Janssen’s antidepressant nasal spray between patients in Scotland and those in England and the rest of the UK may be due to the differences in methodologies and approaches used by the health technology assessment bodies.
You may also be interested in...
UK health technology assessment body NICE says the cost-effectiveness estimates for the nasal spray for treating hard-to-treat depression are much higher than what it considers to be cost-effective.
New medicines under evaluation at the European Medicines Agency.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.